Aripiprazole augmentation, antidepressant combination or switching therapy in patients with major depressive disorder who are partial- or non-responsive to current antidepressants: A multi-center, naturalistic study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Han, Changsu | - |
dc.contributor.author | Wang, Sheng-Min | - |
dc.contributor.author | Seo, Ho-Jun | - |
dc.contributor.author | Lee, Boung Chul | - |
dc.contributor.author | Jeon, Hong Jin | - |
dc.contributor.author | Kim, Won | - |
dc.contributor.author | Kwak, Kyung-Phil | - |
dc.contributor.author | Pae, Chi-Un | - |
dc.date.accessioned | 2021-09-05T11:34:53Z | - |
dc.date.available | 2021-09-05T11:34:53Z | - |
dc.date.created | 2021-06-15 | - |
dc.date.issued | 2014-02 | - |
dc.identifier.issn | 0022-3956 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/99350 | - |
dc.description.abstract | There has been no studies comparing the clinical benefits of aripiprazole augmentation (AT), antidepressant combination (AC), and switching to a different antidepressant (SW) in patients with major depressive disorder (MDD) patients partially or not responding to an initial antidepressant. AT, AC, or SW was chosen by patients. The primary efficacy measure was the proportion of patients showing an improvement in the Clinical Global Impression-Clinical Benefit (CGI-CB) score at week 8. Secondary efficacy measures included changes in CGI-CB, CGI-Severity (S) and subjective satisfaction scores. Remission and responder analysis were also employed. A total of 295 patients were enrolled. The most preferred strategy was AT (n = 156, 52.9%), followed by AC (n = 93, 31.5%) and SW (n = 46, 15.6%). The improver was significantly higher in AT (74.1%) compared with AC (48.1%; p < 0.001) and similar to SW (73.5%, p = 0.948), whereas no significant difference was found between AC and SW. Similar results were also found in the most secondary endpoint measures proving a superiority of AT over AC without differences between AT and SW. Tolerability profiles were similar across the three groups; however, the mean weight gain for SW (-0.1 kg) was significantly less than that for AC (1.3 kg, p < 0.05). Patients preferred AT to AC or SW when an antidepressant was ineffective in treating their depression. Among the three treatment strategies, overall AT yielded greater clinical benefit than did AC and SW. Adequately powered, well-controlled clinical trials are strongly warranted to confirm our findings due to methodological shortcomings. (C) 2013 Elsevier Ltd. All rights reserved. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | PERGAMON-ELSEVIER SCIENCE LTD | - |
dc.subject | SEROTONIN REUPTAKE INHIBITOR | - |
dc.subject | LOW-DOSE ARIPIPRAZOLE | - |
dc.subject | STAR-ASTERISK-D | - |
dc.subject | DOUBLE-BLIND | - |
dc.subject | INADEQUATE-RESPONSE | - |
dc.subject | 2ND-GENERATION ANTIPSYCHOTICS | - |
dc.subject | ADJUNCTIVE THERAPY | - |
dc.subject | TERM OUTCOMES | - |
dc.subject | EFFICACY | - |
dc.subject | SAFETY | - |
dc.title | Aripiprazole augmentation, antidepressant combination or switching therapy in patients with major depressive disorder who are partial- or non-responsive to current antidepressants: A multi-center, naturalistic study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Han, Changsu | - |
dc.identifier.doi | 10.1016/j.jpsychires.2013.11.001 | - |
dc.identifier.scopusid | 2-s2.0-84891154322 | - |
dc.identifier.wosid | 000329772800011 | - |
dc.identifier.bibliographicCitation | JOURNAL OF PSYCHIATRIC RESEARCH, v.49, pp.75 - 82 | - |
dc.relation.isPartOf | JOURNAL OF PSYCHIATRIC RESEARCH | - |
dc.citation.title | JOURNAL OF PSYCHIATRIC RESEARCH | - |
dc.citation.volume | 49 | - |
dc.citation.startPage | 75 | - |
dc.citation.endPage | 82 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | ssci | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Psychiatry | - |
dc.relation.journalWebOfScienceCategory | Psychiatry | - |
dc.subject.keywordPlus | SEROTONIN REUPTAKE INHIBITOR | - |
dc.subject.keywordPlus | LOW-DOSE ARIPIPRAZOLE | - |
dc.subject.keywordPlus | STAR-ASTERISK-D | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | INADEQUATE-RESPONSE | - |
dc.subject.keywordPlus | 2ND-GENERATION ANTIPSYCHOTICS | - |
dc.subject.keywordPlus | ADJUNCTIVE THERAPY | - |
dc.subject.keywordPlus | TERM OUTCOMES | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordAuthor | Augmentation | - |
dc.subject.keywordAuthor | Combination | - |
dc.subject.keywordAuthor | Switching | - |
dc.subject.keywordAuthor | Depression | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.